Ispinesib, also known as SB-715992, is a small molecule inhibitor of kinesin spindle protein (KSP), which is involved in cell division. It was first discovered in 2002 and has since been studied for its potential as a cancer treatment.
Chemical name:
The chemical name for Ispinesib is (R)-3-(4-methylphenyl)-N-[(1S)-1-phenylethyl]propanamide.
Molecular formula:
The molecular formula of Ispinesib is C22H25NO.
Formula weight:
The formula weight of Ispinesib is 323.44 g/mol.
CAS No:
The CAS number of Ispinesib is 336113-53-2.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
Ispinesib has been primarily developed for the treatment of cancer. It is a selective inhibitor of KSP, which plays an important role in the segregation of chromosomes during cell division. By inhibiting KSP, Ispinesib may disrupt the normal cell division process and slow or stop the growth of cancer cells.
Potential effects:
Some potential effects of Ispinesib include:
Product mechanism:
Ispinesib works by inhibiting KSP, which is a motor protein that plays an important role in the separation and movement of chromosomes during cell division. KSP is essential for the proper formation of the microtubule spindle, which is necessary for the segregation of chromosomes. By inhibiting KSP, Ispinesib may disrupt the normal cell division process and slow or stop the growth of cancer cells.
Safety:
Ispinesib has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with Ispinesib.
Side effects:
Ispinesib can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of Ispinesib has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 0.1 to 4 μg/mL. In clinical trials, doses ranged from 12 to 20 mg/m2 per day. The drug is typically administered intravenously.
Conclusion:
Ispinesib is a small molecule inhibitor of KSP that has shown potential as a treatment for cancer. By inhibiting KSP, Ispinesib may disrupt the normal cell division process and slow or stop the growth of cancer cells. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of Ispinesib in treating cancer.
